Achillion (ACHN) Announces Encouraging Interim Results from Phase 2a Trial for Genotype 1 Treatment-Naïve HCV
An innovative all-oral combination therapy for treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) has yielded encouraging results during the phase 2a study conducted by Janssen Pharmaceutical Companies’ Alios BioPharma, Inc., according to a recent press release from Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), the proponents of this therapy. The interim results, compiled by July 2016, were published as part of the abstracts for the upcoming special conference of the European Association for the Study of the Liver (EASL), scheduled for September 23-24 in Paris. Updated results will be released separately on September 23. According to Achillion, a science-driven…







